Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients

Understanding the mechanisms of acquired resistance to anti-PD-1 will allow development of better treatment strategies for cancer patients. This study evaluated potential mechanisms of acquired resistance to anti-PD-1 in longitudinally collected metastatic melanoma patient biopsies. Thirty-four meta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2017-12, Vol.30 (12), p.1666-1676
Hauptverfasser:	Kakavand, Hojabr, Jackett, Louise A, Menzies, Alexander M, Gide, Tuba N, Carlino, Matteo S, Saw, Robyn P M, Thompson, John F, Wilmott, James S, Long, Georgina V, Scolyer, Richard A
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2778 692/308/575 82/51 Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antigen presentation Antineoplastic Agents, Immunological - therapeutic use B7 Antigens - metabolism B7-H1 Antigen - antagonists & inhibitors Biomarkers, Tumor - metabolism Cancer CD8 antigen Clinical trials Disease Progression Drug Resistance, Neoplasm - physiology Female Foxp3 protein Histocompatibility antigen HLA Humans Immune checkpoint Immunohistochemistry Immunotherapy Laboratory Medicine Lymphocytes Lymphocytes T Male Medicine Medicine & Public Health Melanoma Melanoma - drug therapy Metastases Metastasis Middle Aged Monoclonal antibodies Nivolumab original-article Pathology PD-1 protein PD-L1 protein PTEN protein Skin Neoplasms - drug therapy β-Catenin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!